Mesoblast Limited
MEOBF
$1.37
-$0.25-15.43%
Weiss Ratings | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Good | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -1.62 | |||
Price History | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 0.00% | |||
30-Day Total Return | -15.43% | |||
60-Day Total Return | -37.73% | |||
90-Day Total Return | 41.24% | |||
Year to Date Total Return | -37.73% | |||
1-Year Total Return | 128.33% | |||
2-Year Total Return | 85.41% | |||
3-Year Total Return | 59.51% | |||
5-Year Total Return | -28.27% | |||
52-Week High % Change | -74.34% | |||
52-Week Low % Change | 149.09% | |||
Price | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $5.34 | |||
52-Week Low Price | $0.55 | |||
52-Week Low Price (Date) | Apr 23, 2024 | |||
52-Week High Price (Date) | Jan 13, 2025 | |||
Valuation | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.53B | |||
Enterprise Value | 1.62B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.09 | |||
Earnings Per Share Growth | -17.73% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 279.59 | |||
Price/Book (Q) | 3.42 | |||
Enterprise Value/Revenue (TTM) | 304.16 | |||
Price | $1.37 | |||
Enterprise Value/EBITDA (TTM) | -34.89 | |||
Enterprise Value/EBIT | -33.57 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 1.14B | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 61 3 9639 6036 | |||
Address | 55 Collins Street Melbourne, VIC 3000 | |||
Website | www.mesoblast.com | |||
Country | Australia | |||
Year Founded | 2004 | |||
Profitability | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -906.03% | |||
Profit Margin | -1,822.76% | |||
Management Effectiveness | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -4.85% | |||
Return on Equity | -- | |||
Income Statement | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 5.67M | |||
Total Revenue (TTM) | 5.67M | |||
Revenue Per Share | $0.01 | |||
Gross Profit (TTM) | -9.45M | |||
EBITDA (TTM) | -49.43M | |||
EBIT (TTM) | -51.37M | |||
Net Income (TTM) | -103.35M | |||
Net Income Avl. to Common (TTM) | -103.35M | |||
Total Revenue Growth (Q YOY) | -6.85% | |||
Earnings Growth (Q YOY) | -47.31% | |||
EPS Diluted (TTM) | -0.09 | |||
EPS Diluted Growth (Q YOY) | -12.90% | |||
Balance Sheet | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 38.03M | |||
Cash Per Share (Q) | $0.03 | |||
Total Current Assets (Q) | 69.68M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 461.26M | |||
Current Ratio (Q) | 0.958 | |||
Book Value Per Share (Q) | $0.40 | |||
Total Assets (Q) | 653.32M | |||
Total Current Liabilities (Q) | 72.75M | |||
Total Debt (Q) | 126.11M | |||
Total Liabilities (Q) | 192.06M | |||
Total Common Equity (Q) | 461.26M | |||
Cash Flow | MEOBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 618.00K | |||
Cash from Financing (TTM) | 4.39M | |||
Net Change in Cash (TTM) | -39.53M | |||
Levered Free Cash Flow (TTM) | -13.46M | |||
Cash from Operations (TTM) | -42.54M | |||